<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34831081</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2073-4409</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>10</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Oct</Month>
              <Day>23</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cells</Title>
          <ISOAbbreviation>Cells</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Management of Rheumatoid Arthritis: An Overview.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">2857</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/cells10112857</ELocationID>
        <Abstract>
          <AbstractText>Rheumatoid arthritis (RA) is a multifactorial autoimmune disease of unknown etiology, primarily affecting the joints, then extra-articular manifestations can occur. Due to its complexity, which is based on an incompletely elucidated pathophysiological mechanism, good RA management requires a multidisciplinary approach. The clinical status of RA patients has improved in recent years due to medical advances in diagnosis and treatment, that have made it possible to reduce disease activity and prevent systemic complications. The most promising results were obtained by developing disease-modifying anti-rheumatic drugs (DMARDs), the class to which conventional synthetic, biologic, and targeted synthetic drugs belong. Furthermore, ongoing drug development has led to obtaining molecules with improved efficacy and safety profiles, but further research is needed until RA turns into a curable pathology. In the present work, we offer a comprehensive perspective on the management of RA, by centralizing the existing data provided by significant literature, emphasizing the importance of an early and accurate diagnosis associated with optimal personalized treatment in order to achieve better outcomes for RA patients. In addition, this study suggests future research perspectives in the treatment of RA that could lead to higher efficacy and safety profiles and lower financial costs.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Radu</LastName>
            <ForeName>Andrei-Flavius</ForeName>
            <Initials>AF</Initials>
            <AffiliationInfo>
              <Affiliation>Doctoral School of Biological and Biomedical Sciences, University of Oradea, 410087 Oradea, Romania.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bungau</LastName>
            <ForeName>Simona Gabriela</ForeName>
            <Initials>SG</Initials>
            <Identifier Source="ORCID">0000-0003-3236-1292</Identifier>
            <AffiliationInfo>
              <Affiliation>Doctoral School of Biological and Biomedical Sciences, University of Oradea, 410087 Oradea, Romania.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cells</MedlineTA>
        <NlmUniqueID>101600052</NlmUniqueID>
        <ISSNLinking>2073-4409</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001172" MajorTopicYN="N">Arthritis, Rheumatoid</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">DMARDs</Keyword>
        <Keyword MajorTopicYN="Y">Janus kinase inhibitors</Keyword>
        <Keyword MajorTopicYN="Y">anti-citrullinated protein antibodies</Keyword>
        <Keyword MajorTopicYN="Y">extra-articular manifestations</Keyword>
        <Keyword MajorTopicYN="Y">proteins</Keyword>
        <Keyword MajorTopicYN="Y">rheumatoid arthritis</Keyword>
        <Keyword MajorTopicYN="Y">rheumatoid factor</Keyword>
        <Keyword MajorTopicYN="Y">targets</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>27</Day>
          <Hour>1</Hour>
          <Minute>14</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34831081</ArticleId>
        <ArticleId IdType="pmc">PMC8616326</ArticleId>
        <ArticleId IdType="doi">10.3390/cells10112857</ArticleId>
        <ArticleId IdType="pii">cells10112857</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Conforti A., di Cola I., Pavlych V., Ruscitti P., Berardicurti O., Ursini F., Giacomelli R., Cipriani P. Beyond the joints, the extra-articular manifestations in rheumatoid arthritis. Autoimmun. Rev. 2021;20:102735. doi: 10.1016/j.autrev.2020.102735.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.autrev.2020.102735</ArticleId>
            <ArticleId IdType="pubmed">33346115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cojocaru M., Cojocaru I.M., Silosi I., Vrabie C.D., Tanasescu R. Extra-articular manifestations in rheumatoid arthritis. Mædica. 2010;5:286–291.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3152850</ArticleId>
            <ArticleId IdType="pubmed">21977172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joseph A., Brasington R., Kahl L., Ranganathan P., Cheng T.P., Atkinson J. Immunologic rheumatic disorders. J. Allergy Clin. Immunol. 2010;125:S204–S215. doi: 10.1016/j.jaci.2009.10.067.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaci.2009.10.067</ArticleId>
            <ArticleId IdType="pubmed">20176259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kurowska W., Kuca-Warnawin E.H., Radzikowska A., Maśliński W. The role of anti-citrullinated protein antibodies (ACPA) in the pathogenesis of rheumatoid arthritis. Cent. J. Immunol. 2017;42:390–398. doi: 10.5114/ceji.2017.72807.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5114/ceji.2017.72807</ArticleId>
            <ArticleId IdType="pmc">PMC5820977</ArticleId>
            <ArticleId IdType="pubmed">29472818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wegner N., Lundberg K., Kinloch A., Fisher B., Malmström V., Feldmann M., Venables P.J. Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol. Rev. 2010;233:34–54. doi: 10.1111/j.0105-2896.2009.00850.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.0105-2896.2009.00850.x</ArticleId>
            <ArticleId IdType="pubmed">20192991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaurasia N., Singh A., Singh I.L., Singh T., Tiwari T. Cognitive dysfunction in patients of rheumatoid arthritis. J. Fam. Med. Prim. Care. 2020;9:2219–2225. doi: 10.4103/jfmpc.jfmpc_307_20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/jfmpc.jfmpc_307_20</ArticleId>
            <ArticleId IdType="pmc">PMC7380780</ArticleId>
            <ArticleId IdType="pubmed">32754477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lassere M.N., Rappo J., Portek I.J., Sturgess A., Edmonds J.P. How many life years are lost in patients with rheumatoid arthritis? Secular cause-specific and all-cause mortality in rheumatoid arthritis, and their predictors in a long-term Australian cohort study. Intern. Med. J. 2013;43:66–72. doi: 10.1111/j.1445-5994.2012.02727.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1445-5994.2012.02727.x</ArticleId>
            <ArticleId IdType="pubmed">22289054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hootman J.M., Helmick C.G., Brady T.J. A public health approach to addressing arthritis in older adults: The most common cause of disability. Am. J. Public Health. 2012;102:426–433. doi: 10.2105/AJPH.2011.300423.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2105/AJPH.2011.300423</ArticleId>
            <ArticleId IdType="pmc">PMC3487631</ArticleId>
            <ArticleId IdType="pubmed">22390506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Theis K.A., Steinweg A., Helmick C.G., Courtney-Long E., Bolen J.A., Lee R. Which one? What kind? How many? Types, causes, and prevalence of disability among U.S. adults. Disabil. Health J. 2019;12:411–421. doi: 10.1016/j.dhjo.2019.03.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.dhjo.2019.03.001</ArticleId>
            <ArticleId IdType="pubmed">31000498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lanes S.F., Lanza L.L., Radensky P.W., Yood R.A., Meenan R.F., Walker A.M., Dreyer N.A. Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting. The importance of drug and surgery costs. Arthritis Rheum. 1997;40:1475–1481. doi: 10.1002/art.1780400816.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.1780400816</ArticleId>
            <ArticleId IdType="pubmed">9259428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cooper N.J. Economic burden of rheumatoid arthritis: A systematic review. Rheumatology. 2000;39:28–33. doi: 10.1093/rheumatology/39.1.28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/39.1.28</ArticleId>
            <ArticleId IdType="pubmed">10662870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo Q., Wang Y., Xu D., Nossent J., Pavlos N.J., Xu J. Rheumatoid arthritis: Pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018;6:1–15. doi: 10.1038/s41413-018-0016-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41413-018-0016-9</ArticleId>
            <ArticleId IdType="pmc">PMC5920070</ArticleId>
            <ArticleId IdType="pubmed">29736302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh J.A., Saag K.G., Bridges S.L., Akl E.A., Bannuru R.R., Sullivan M.C., Vaysbrot E., McNaughton C., Osani M., Shmerling R.H., et al.  2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68:1–26. doi: 10.1002/art.39480.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.39480</ArticleId>
            <ArticleId IdType="pubmed">26545940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moura M.D.G., Lopes L.C., Silva M.T., Barberato-Filho S., Motta R.H.L., Bergamaschi C.C. Use of steroid and nonsteroidal anti-inflammatories in the treatment of rheumatoid arthritis: Systematic review protocol. Medicine. 2018;97:e12658. doi: 10.1097/MD.0000000000012658.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MD.0000000000012658</ArticleId>
            <ArticleId IdType="pmc">PMC6203474</ArticleId>
            <ArticleId IdType="pubmed">30313057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Safiri S., Kolahi A.A., Hoy D., Smith E., Bettampadi D., Mansournia M.A., Almasi-Hashiani A., Ashrafi-Asgarabad A., Moradi-Lakeh M., Qorbani M., et al.  Global, regional and national burden of rheumatoid arthritis 1990–2017: A systematic analysis of the global burden of disease study 2017. Ann. Rheum. Dis. 2019;78:1463–1471. doi: 10.1136/annrheumdis-2019-215920.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2019-215920</ArticleId>
            <ArticleId IdType="pubmed">31511227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stojanovic R.S., Vlajinac Stojanovic H., Palic D., Palic P., Obradovic O., Evic Obradovic S.J. Prevalence of rheumatoid arthritis in Belgrade, Yugoslavia. Br. J. Rheumatol. 1998;37:729–732. doi: 10.1093/rheumatology/37.7.729.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/37.7.729</ArticleId>
            <ArticleId IdType="pubmed">9714347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Silman A.J., Hochberg M.  Descriptive epidemiology of rheumatoid arthritis. In: Hetherington P., Ingram J., Forgione L., editors. Rheumatoid Arthritis. Mosby; Maryland Heights, MO, USA: Elsevier; Philadelphia, PA, USA: 2009. pp. 15–22.</Citation>
        </Reference>
        <Reference>
          <Citation>Guillemin F., Saraux A., Guggenbuhl P., Roux C.H., Fardellone P., Le Bihan E., Cantagrel A., Chary-Valckenaere I., Euller-Ziegler L., Flipo R.M., et al.  Prevalence of rheumatoid arthritis in France: 2001. Ann. Rheum. Dis. 2005;64:1427–1430. doi: 10.1136/ard.2004.029199.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/ard.2004.029199</ArticleId>
            <ArticleId IdType="pmc">PMC1755224</ArticleId>
            <ArticleId IdType="pubmed">15800010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cimmino M.A., Parisi M., Moggiana G., Mela G.S., Accardo S. Prevalence of rheumatoid arthritis in Italy: The Chiavari study. Ann. Rheum. Dis. 1998;57:315–318. doi: 10.1136/ard.57.5.315.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/ard.57.5.315</ArticleId>
            <ArticleId IdType="pmc">PMC1752594</ArticleId>
            <ArticleId IdType="pubmed">9741317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shichikawa K., Inoue K., Hirota S., Maeda A., Ota H., Kimura M., Ushiyama T., Tsujimoto M. Changes in the incidence and prevalence of rheumatoid arthritis in Kamitonda, Wakayama, Japan, 1965–1996. Ann. Rheum. Dis. 1999;58:751–756. doi: 10.1136/ard.58.12.751.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/ard.58.12.751</ArticleId>
            <ArticleId IdType="pmc">PMC1752814</ArticleId>
            <ArticleId IdType="pubmed">10577961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spindler A., Bellomio V., Berman A., Lucero E., Baigorria M., Paz S., Garrone N., Torres A.I., Romano O., Carraccio A., et al.  Prevalence of rheumatoid arthritis in Tucumán, Argentina. J. Rheumatol. 2002;29:1166–1170.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12064829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zlatković-Švenda M.I., Stojanović R.M.B., Šipetić-Grujičić S., Guillemin F. Prevalence of rheumatoid arthritis in Serbia. Rheumatol. Int. 2013;34:649–658. doi: 10.1007/s00296-013-2897-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00296-013-2897-7</ArticleId>
            <ArticleId IdType="pubmed">24292809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rossini M., Rossi E., Bernardi D., Viapiana O., Gatti D., Idolazzi L., Caimmi C., DeRosa M., Adami S. Prevalence and incidence of rheumatoid arthritis in Italy. Rheumatol. Int. 2014;34:659–664. doi: 10.1007/s00296-014-2974-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00296-014-2974-6</ArticleId>
            <ArticleId IdType="pubmed">24610538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kojima M., Nakayama T., Tsutani K., Igarashi A., Kojima T., Suzuki S., Miyasaka N., Yamanaka H. Epidemiological characteristics of rheumatoid arthritis in Japan: Prevalence estimates using a nationwide population-based questionnaire survey. Mod. Rheumatol. 2019;30:941–947. doi: 10.1080/14397595.2019.1682776.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14397595.2019.1682776</ArticleId>
            <ArticleId IdType="pubmed">31625435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tian X., Wang Q., Li M., Zhao Y., Zhang Z., Huang C., Liu Y., Xu H., Chen Y., Wu L., et al.  2018 Chinese guidelines for the diagnosis and treatment of rheumatoid arthritis. Rheumatol. Immunol. Res. 2021;2:1–14. doi: 10.2478/rir-2021-0002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2478/rir-2021-0002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scublinsky D., Venarotti H., Citera G., Messina O.D., Scheines E., Rillo O., Arturi A., Hofman J., Somma L.F., Casado G., et al.  The prevalence of rheumatoid arthritis in Argentina: A capture-recapture study in a city of Buenos Aires Province. J. Clin. Rheumatol. 2010;16:317–321. doi: 10.1097/RHU.0b013e3181f3bfdd.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/RHU.0b013e3181f3bfdd</ArticleId>
            <ArticleId IdType="pubmed">20859227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carmona L., Villaverde V., Hernández-García C., Ballina J., Gabriel R., Laffon A. The prevalence of rheumatoid arthritis in the general population of Spain. Rheumatology. 2002;41:88–95. doi: 10.1093/rheumatology/41.1.88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/41.1.88</ArticleId>
            <ArticleId IdType="pubmed">11792885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Silva-Fernández L., Macía-Villa C., Seoane-Mato D., Cortés-Verdú R., Romero-Pérez A., Quevedo-Vila V., Fábregas-Canales D., Antón-Pagés F., Añez G., Brandy A., et al.  The prevalence of rheumatoid arthritis in Spain. Sci. Rep. 2020;10:1–9. doi: 10.1038/s41598-020-76511-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-020-76511-6</ArticleId>
            <ArticleId IdType="pmc">PMC7725786</ArticleId>
            <ArticleId IdType="pubmed">33299019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akar S., Birlik M., Gurler O., Sari I., Onen F., Manisali M., Tirpan K., Demir T., Meral M., Akkoç N. The prevalence of rheumatoid arthritis in an urban population of Izmir-Turkey. Clin. Exp. Rheumatol. 2004;22:416–420.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15301237</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tuncer T., Gilgil E., Kaçar C., Kurtaiş Y., Kutlay Ş., Bütün B., Yalçin P., Akarirmak Ü., Altan L., Ardiç F., et al.  Prevalence of rheumatoid arthritis and spondyloarthritis in Turkey: A nationwide study. Arch. Rheumatol. 2018;33:128–136. doi: 10.5606/ArchRheumatol.2018.6480.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5606/ArchRheumatol.2018.6480</ArticleId>
            <ArticleId IdType="pmc">PMC6117145</ArticleId>
            <ArticleId IdType="pubmed">30207568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smolen J.S., Aletaha D., McInnes I.B. Rheumatoid arthritis. Lancet. 2016;388:2023–2038. doi: 10.1016/S0140-6736(16)30173-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(16)30173-8</ArticleId>
            <ArticleId IdType="pubmed">27156434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guillemin F., Briançon S., Klein J.M., Sauleau E., Pourel J. Low incidence of rheumatoid arthritis in France. Scand. J. Rheumatol. 2009;23:264–268. doi: 10.3109/03009749409103727.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/03009749409103727</ArticleId>
            <ArticleId IdType="pubmed">7973481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doran M.F., Pond G.R., Crowson C.S., O’Fallon W.M., Gabriel S.E. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum. 2002;46:625–631. doi: 10.1002/art.509.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.509</ArticleId>
            <ArticleId IdType="pubmed">11920397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Myasoedova E., Davis J., Matteson E.L., Crowson C.S. Is the epidemiology of rheumatoid arthritis changing? Results from a population-based incidence study, 1985–2014. Ann. Rheum. Dis. 2020;79:440–444. doi: 10.1136/annrheumdis-2019-216694.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2019-216694</ArticleId>
            <ArticleId IdType="pmc">PMC7085464</ArticleId>
            <ArticleId IdType="pubmed">32066556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taylor-Gjevre R., Nair B., Jin S., Quail J. Geographic variation in incidence and prevalence rates for rheumatoid arthritis in Saskatchewan, Canada 2001–2014. Can. J. Public Health. 2018;109:427–435. doi: 10.17269/s41997-018-0045-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.17269/s41997-018-0045-6</ArticleId>
            <ArticleId IdType="pmc">PMC6964385</ArticleId>
            <ArticleId IdType="pubmed">29981076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costenbader K.H., Chang S.-C., Laden F., Puett R., Karlson E.W. Geographic variation in rheumatoid arthritis incidence among women in the United States. Arch. Intern. Med. 2008;168:1664–1670. doi: 10.1001/archinte.168.15.1664.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archinte.168.15.1664</ArticleId>
            <ArticleId IdType="pmc">PMC2732358</ArticleId>
            <ArticleId IdType="pubmed">18695080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parks C.G., D’Aloisio A.A., DeRoo L.A., Huiber K., Rider L.G., Miller F.W., Sandler D.P. Childhood socioeconomic factors and perinatal characteristics influence development of rheumatoid arthritis in adulthood. Ann. Rheum. Dis. 2013;72:350–356. doi: 10.1136/annrheumdis-2011-201083.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2011-201083</ArticleId>
            <ArticleId IdType="pmc">PMC5029277</ArticleId>
            <ArticleId IdType="pubmed">22586176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Almoallim H., Al Saleh J., Badsha H., Ahmed H.M., Habjoka S., Menassa J.A., El-Garf A. A Review of the prevalence and unmet needs in the management of rheumatoid arthritis in Africa and the Middle East. Rheumatol. Ther. 2020;8:1–16. doi: 10.1007/s40744-020-00252-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40744-020-00252-1</ArticleId>
            <ArticleId IdType="pmc">PMC7991016</ArticleId>
            <ArticleId IdType="pubmed">33226566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts-Thomson P.J., Jones M.E., Walker J.G., Macfarlane J.G., Smith M.D., Ahern M.J. Stochastic processes in the causation of rheumatic disease. J. Rheumatol. 2002;29:2628–2634.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12465164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petrovská N., Prajzlerová K., Vencovský J., Šenolt L., Filková M. The pre-clinical phase of rheumatoid arthritis: From risk factors to prevention of arthritis. Autoimmun. Rev. 2021;20:102797. doi: 10.1016/j.autrev.2021.102797.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.autrev.2021.102797</ArticleId>
            <ArticleId IdType="pubmed">33746022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Macgregor A.J., Snieder H., Rigby A.S., Koskenvuo M., Kaprio J., Aho K., Silman A.J. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum. 2000;43:30–37. doi: 10.1002/1529-0131(200001)43:1&lt;30::AID-ANR5&gt;3.0.CO;2-B.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1529-0131(200001)43:1&lt;30::AID-ANR5&gt;3.0.CO;2-B</ArticleId>
            <ArticleId IdType="pubmed">10643697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van der Helm-van Mil A.H.M., Verpoort K.N., Breedveld F.C., Huizinga T.W.J., Toes R.E.M., Vries R.R.P. The HLA–DRB1 shared epitope alleles are primarily a risk factor for anti–cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum. 2006;54:1117–1121. doi: 10.1002/art.21739.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.21739</ArticleId>
            <ArticleId IdType="pubmed">16572446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ding B., Padyukov L., Lundström E., Seielstad M., Plenge R.M., Oksenberg J.R., Gregersen P.K., Alfredsson L., Klareskog L. Different patterns of associations with anti–citrullinated protein antibody–positive and anti–citrullinated protein antibody–negative rheumatoid arthritis in the extended major histocompatibility complex region. Arthritis Rheum. 2009;60:30–38. doi: 10.1002/art.24135.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.24135</ArticleId>
            <ArticleId IdType="pmc">PMC2874319</ArticleId>
            <ArticleId IdType="pubmed">19116921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kokkonen H., Johansson M., Innala L., Jidell E., Rantapää-Dahlqvist S. The PTPN221858C/T polymorphism is associated with anti-cyclic citrullinated peptide antibody-positive early rheumatoid arthritis in northern Sweden. Arthritis Res. Ther. 2007;9:1–7. doi: 10.1186/ar2312.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/ar2312</ArticleId>
            <ArticleId IdType="pmc">PMC2206338</ArticleId>
            <ArticleId IdType="pubmed">17553139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Källberg H., Padyukov L., Plenge R.M., Rönnelid J., Gregersen P.K., van der Helmvan Mil A.H.M., Toes R.E.M., Huizinga T.W., Klareskog L., Alfredsson L., et al.  Gene-Gene and Gene-Environment Interactions Involving HLA-DRB1, PTPN22, and Smoking in Two Subsets of Rheumatoid Arthritis. Am. J. Hum. Genet. 2007;80:867–875. doi: 10.1086/516736.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1086/516736</ArticleId>
            <ArticleId IdType="pmc">PMC1852748</ArticleId>
            <ArticleId IdType="pubmed">17436241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X., Li W., Zhang X., Zhang X., Jiang L., Guo Y., Wang X. Association between polymorphism in TRAF1/C5 gene and risk of rheumatoid arthritis: A meta-analysis. Mol. Biol. Rep. 2013;41:317–324. doi: 10.1007/s11033-013-2864-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11033-013-2864-0</ArticleId>
            <ArticleId IdType="pubmed">24234752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sigurdsson S., Padyukov L., Kurreeman F.A.S., Liljedahl U., Wiman A.-C., Alfredsson L., Toes R., Rönnelid J., Klareskog L., Huizinga T.W.J., et al.  Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis. Arthritis Rheum. 2007;56:2202–2210. doi: 10.1002/art.22704.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.22704</ArticleId>
            <ArticleId IdType="pubmed">17599733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vessey M.P., Villard-Mackintosh L., Yeates D. Oral contraceptives, cigarette smoking and other factors in relation to arthritis. Contraception. 1987;35:457–464. doi: 10.1016/0010-7824(87)90082-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0010-7824(87)90082-5</ArticleId>
            <ArticleId IdType="pubmed">3621942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liao K.P., Alfredsson L., Karlson E.W. Environmental influences on risk for rheumatoid arthritis. Curr. Opin. Rheumatol. 2009;21:279–283. doi: 10.1097/BOR.0b013e32832a2e16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/BOR.0b013e32832a2e16</ArticleId>
            <ArticleId IdType="pmc">PMC2898190</ArticleId>
            <ArticleId IdType="pubmed">19318947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ishikawa Y., Terao C. The impact of cigarette smoking on risk of rheumatoid arthritis: A narrative review. Cells. 2020;9:475.  doi: 10.3390/cells9020475.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cells9020475</ArticleId>
            <ArticleId IdType="pmc">PMC7072747</ArticleId>
            <ArticleId IdType="pubmed">32092988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Linn-Rasker S.P., van der Mil A.H.M.H., van Gaalen F.A., Kloppenburg M., de Vries R.R.P., le Cessie S., Breedveld F.C., Toes R.E.M., Huizinga T.W.J. Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. Ann. Rheum. Dis. 2006;65:366–371. doi: 10.1136/ard.2005.041079.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/ard.2005.041079</ArticleId>
            <ArticleId IdType="pmc">PMC1798061</ArticleId>
            <ArticleId IdType="pubmed">16014670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Padyukov L., Silva C., Stolt P., Alfredsson L., Klareskog L. A gene–environment interaction between smoking and shared epitope genes in HLA–DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum. 2004;50:3085–3092. doi: 10.1002/art.20553.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.20553</ArticleId>
            <ArticleId IdType="pubmed">15476204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hedström A.K., Klareskog L., Alfredsson L. Exposure to passive smoking and rheumatoid arthritis risk: Results from the Swedish EIRA study. Ann. Rheum. Dis. 2018;77:970–972. doi: 10.1136/annrheumdis-2018-212973.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2018-212973</ArticleId>
            <ArticleId IdType="pmc">PMC6029632</ArticleId>
            <ArticleId IdType="pubmed">29724731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mehri F., Jenabi E., Bashirian S., Shahna F.G., Khazaei S. The association between occupational exposure to silica and risk of developing rheumatoid arthritis: A meta-analysis. Saf. Health Work. 2020;11:136–142. doi: 10.1016/j.shaw.2020.02.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.shaw.2020.02.001</ArticleId>
            <ArticleId IdType="pmc">PMC7303526</ArticleId>
            <ArticleId IdType="pubmed">32596007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alaya Z., Braham M., Aissa S., Kalboussi H., Bouajina E. A case of Caplan syndrome in a recently diagnosed patient with silicosis: A case report. Radiol. Case Rep. 2018;13:663–666. doi: 10.1016/j.radcr.2018.03.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.radcr.2018.03.004</ArticleId>
            <ArticleId IdType="pmc">PMC6046370</ArticleId>
            <ArticleId IdType="pubmed">30023036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jin J., Li J., Gan Y., Liu J., Zhao X., Chen J., Zhang R., Zhong Y., Chen X., Wu L., et al.  Red meat intake is associated with early onset of rheumatoid arthritis: A cross-sectional study. Sci. Rep. 2021;11:1–7. doi: 10.1038/s41598-021-85035-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-021-85035-6</ArticleId>
            <ArticleId IdType="pmc">PMC7952581</ArticleId>
            <ArticleId IdType="pubmed">33707573</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pattison D.J., Harrison R.A., Symmons D.P.M. The role of diet in susceptibility to rheumatoid arthritis: A systematic review. J. Rheumatol. 2004;31:1310–1319.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15229949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karlson E.W., Mandl L.A., Aweh G.N., Grodstein F. Coffee consumption and risk of rheumatoid arthritis. Arthritis Rheum. 2003;48:3055–3060. doi: 10.1002/art.11306.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.11306</ArticleId>
            <ArticleId IdType="pubmed">14613266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mehta B., Pedro S., Ozen G., Kalil A., Wolfe F., Mikuls T., Michaud K. Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: A US national cohort study. RMD Open. 2019;5:e000935. doi: 10.1136/rmdopen-2019-000935.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/rmdopen-2019-000935</ArticleId>
            <ArticleId IdType="pmc">PMC6560658</ArticleId>
            <ArticleId IdType="pubmed">31245055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feder H.M.J., Johnson B.J.B., O’Connell S., Shapiro E.D., Steere A.C., Wormser G.P. A critical appraisal of “chronic lyme disease”. N. Engl. J. Med. 2009;357:1422–1430. doi: 10.1056/NEJMra072023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra072023</ArticleId>
            <ArticleId IdType="pubmed">17914043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perricone C., Ceccarelli F., Saccucci M., di Carlo G., Bogdanos D.P., Lucchetti R., Pilloni A., Valesini G., Polimeni A., Conti F. Porphyromonas gingivalis and rheumatoid arthritis. Curr. Opin. Rheumatol. 2019;31:517–524. doi: 10.1097/BOR.0000000000000638.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/BOR.0000000000000638</ArticleId>
            <ArticleId IdType="pubmed">31268867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Firestein G.S., McInnes I.B. Immunopathogenesis of rheumatoid arthritis. Immunity. 2017;46:183–196. doi: 10.1016/j.immuni.2017.02.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2017.02.006</ArticleId>
            <ArticleId IdType="pmc">PMC5385708</ArticleId>
            <ArticleId IdType="pubmed">28228278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Curran A.M., Naik P., Giles J.T., Darrah E. PAD enzymes in rheumatoid arthritis: Pathogenic effectors and autoimmune targets. Nat. Rev. Rheumatol. 2020;16:301–315. doi: 10.1038/s41584-020-0409-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41584-020-0409-1</ArticleId>
            <ArticleId IdType="pubmed">32341463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scherer H.U., Häupl T., Burmester G.R. The etiology of rheumatoid arthritis. J. Autoimmun. 2020;110:102400. doi: 10.1016/j.jaut.2019.102400.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaut.2019.102400</ArticleId>
            <ArticleId IdType="pubmed">31980337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Damerau A., Gaber T. Modeling rheumatoid arthritis in vitro: From experimental feasibility to physiological proximity. Int. J. Mol. Sci. 2020;21:7916.  doi: 10.3390/ijms21217916.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms21217916</ArticleId>
            <ArticleId IdType="pmc">PMC7663779</ArticleId>
            <ArticleId IdType="pubmed">33113770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Drongelen V., Holoshitz J. HLA-disease associations in rheumatoid arthritis. Rheum. Dis. Clin. North Am. 2017;43:363–376. doi: 10.1016/j.rdc.2017.04.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.rdc.2017.04.003</ArticleId>
            <ArticleId IdType="pmc">PMC5643023</ArticleId>
            <ArticleId IdType="pubmed">28711139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frauwirth K.A., Thompson C.B. Activation and inhibition of lymphocytes by costimulation. J. Clin. Investig. 2002;109:295–299. doi: 10.1172/JCI0214941.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI0214941</ArticleId>
            <ArticleId IdType="pmc">PMC150864</ArticleId>
            <ArticleId IdType="pubmed">11827987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Isaacs J.D. Therapeutic T-cell manipulation in rheumatoid arthritis: Past, present and future. Rheumatology. 2008;47:1461–1468. doi: 10.1093/rheumatology/ken163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/ken163</ArticleId>
            <ArticleId IdType="pubmed">18503092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stavnezer J., Guikema J.E.J., Schrader C.E. Mechanism and regulation of class switch recombination. Annu. Rev. Immunol. 2008;26:261–292. doi: 10.1146/annurev.immunol.26.021607.090248.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.immunol.26.021607.090248</ArticleId>
            <ArticleId IdType="pmc">PMC2707252</ArticleId>
            <ArticleId IdType="pubmed">18370922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ingegnoli F., Castelli R., Gualtierotti R. Rheumatoid factors: Clinical applications. Dis. Markers. 2013;35:727–734. doi: 10.1155/2013/726598.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2013/726598</ArticleId>
            <ArticleId IdType="pmc">PMC3845430</ArticleId>
            <ArticleId IdType="pubmed">24324289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu H.C., Lu M.C. The roles of anti-citrullinated protein antibodies in the immunopathogenesis of rheumatoid arthritis. Tzu-Chi Med. J. 2019;31:5–10. doi: 10.4103/TCMJ.TCMJ_116_18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/TCMJ.TCMJ_116_18</ArticleId>
            <ArticleId IdType="pmc">PMC6334572</ArticleId>
            <ArticleId IdType="pubmed">30692825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Essouma M., Noubiap J.J.N. Is air pollution a risk factor for rheumatoid arthritis? J. Inflamm. 2015;12:48. doi: 10.1186/s12950-015-0092-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12950-015-0092-1</ArticleId>
            <ArticleId IdType="pmc">PMC4518680</ArticleId>
            <ArticleId IdType="pubmed">26225124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alsaber A., Pan J., Al-Herz A., Alkandary D.S., Al-Hurban A., Setiya P., KRRD Group  Influence of ambient air pollution on rheumatoid arthritis disease activity score index. Int. J. Environ. Res. Public Health. 2020;17:416.  doi: 10.3390/ijerph17020416.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijerph17020416</ArticleId>
            <ArticleId IdType="pmc">PMC7013841</ArticleId>
            <ArticleId IdType="pubmed">31936295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adami G., Viapiana O., Rossini M., Orsolini G., Bertoldo E., Giollo A., Gatti D., Fassio A. Association between environmental air pollution and rheumatoid arthritis flares. Rheumatology. 2021;60:4591–4597. doi: 10.1093/rheumatology/keab049.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/keab049</ArticleId>
            <ArticleId IdType="pubmed">33470401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song G.G., Bae S.-C., Lee Y.H. Association between vitamin D intake and the risk of rheumatoid arthritis: A meta-analysis. Clin. Rheumatol. 2012;31:1733–1739. doi: 10.1007/s10067-012-2080-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10067-012-2080-7</ArticleId>
            <ArticleId IdType="pubmed">22941259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maeda Y., Takeda K. Host–microbiota interactions in rheumatoid arthritis. Exp. Mol. Med. 2019;51:1–6. doi: 10.1038/s12276-019-0283-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s12276-019-0283-6</ArticleId>
            <ArticleId IdType="pmc">PMC6906371</ArticleId>
            <ArticleId IdType="pubmed">31827063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wells P.M., Williams F.M.K., Matey-Hernandez M.L., Menni C., Steves C.J. RA and the microbiome: Do host genetic factors provide the link? J. Autoimmun. 2019;99:104–115. doi: 10.1016/j.jaut.2019.02.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaut.2019.02.004</ArticleId>
            <ArticleId IdType="pmc">PMC6470121</ArticleId>
            <ArticleId IdType="pubmed">30850234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li M., Wang F. Role of intestinal microbiota on gut homeostasis and rheumatoid arthritis. J. Immunol. Res. 2021;2021:1–9. doi: 10.1155/2021/8167283.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2021/8167283</ArticleId>
            <ArticleId IdType="pmc">PMC8203374</ArticleId>
            <ArticleId IdType="pubmed">34195296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vandeputte D., Kathagen G., D’hoe K., Vieira-Silva S., Valles-Colomer M., Sabino J., Wang J., Tito R.Y., de Commer L., Darzi Y., et al.  Quantitative microbiome profiling links gut community variation to microbial load. Nature. 2017;551:507–511. doi: 10.1038/nature24460.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature24460</ArticleId>
            <ArticleId IdType="pubmed">29143816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Croia C., Bursi R., Sutera D., Petrelli F., Alunno A., Puxeddu I. One year in review 2019: Pathogenesis of rheumatoid arthritis. Clin. Exp. Rheumatol. 2019;37:347–357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31111823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hannemann N., Apparailly F., Courties G. Synovial macrophages: From ordinary eaters to extraordinary multitaskers. Trends Immunol. 2021;42:368–371. doi: 10.1016/j.it.2021.03.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.it.2021.03.002</ArticleId>
            <ArticleId IdType="pubmed">33832864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bartok B., Firestein G.S. Fibroblast-like synoviocytes: Key effector cells in rheumatoid arthritis. Immunol. Rev. 2010;233:233–255. doi: 10.1111/j.0105-2896.2009.00859.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.0105-2896.2009.00859.x</ArticleId>
            <ArticleId IdType="pmc">PMC2913689</ArticleId>
            <ArticleId IdType="pubmed">20193003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Itoh Y. Metalloproteinases in rheumatoid arthritis: Potential therapeutic targets to improve current therapies. Prog. Mol. Biol. Transl. Sci. 2017;148:327–338. doi: 10.1016/BS.PMBTS.2017.03.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/BS.PMBTS.2017.03.002</ArticleId>
            <ArticleId IdType="pubmed">28662826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yasuda T. Cartilage destruction by matrix degradation products. Mod. Rheumatol. 2006;16:197–205. doi: 10.3109/s10165-006-0490-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/s10165-006-0490-6</ArticleId>
            <ArticleId IdType="pmc">PMC2780665</ArticleId>
            <ArticleId IdType="pubmed">16906368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geusens P. The role of RANK ligand/osteoprotegerin in rheumatoid arthritis. Ther. Adv. Musculoskelet. Dis. 2012;4:225–233. doi: 10.1177/1759720X12438080.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1759720X12438080</ArticleId>
            <ArticleId IdType="pmc">PMC3403250</ArticleId>
            <ArticleId IdType="pubmed">22859921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lundy S.K., Sarkar S., Tesmer L.A., Fox D.A. Cells of the synovium in rheumatoid arthritis. T lymphocytes. Arthritis Res. Ther. 2007;9:202. doi: 10.1186/ar2107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/ar2107</ArticleId>
            <ArticleId IdType="pmc">PMC1860060</ArticleId>
            <ArticleId IdType="pubmed">17306038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kehlen A., Thiele K., Riemann D., Langner J. Expression, modulation and signalling of IL-17 receptor in fibroblast-like synoviocytes of patients with rheumatoid arthritis. Clin. Exp. Immunol. 2002;127:539–546. doi: 10.1046/j.1365-2249.2002.01782.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1365-2249.2002.01782.x</ArticleId>
            <ArticleId IdType="pmc">PMC1906300</ArticleId>
            <ArticleId IdType="pubmed">11966773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yap H.Y., Tee S.Z.Y., Wong M.M.T., Chow S.K., Peh S.C., Teow S.Y. Pathogenic role of immune cells in rheumatoid arthritis: Implications in clinical treatment and biomarker development. Cells. 2018;7:161.  doi: 10.3390/cells7100161.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cells7100161</ArticleId>
            <ArticleId IdType="pmc">PMC6211121</ArticleId>
            <ArticleId IdType="pubmed">30304822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Phull A.R., Nasir B., Haq I.U., Kim S.J. Oxidative stress, consequences and ROS mediated cellular signaling in rheumatoid arthritis. Chem. Biol. Interact. 2018;281:121–136. doi: 10.1016/j.cbi.2017.12.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cbi.2017.12.024</ArticleId>
            <ArticleId IdType="pubmed">29258867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abbas M., Monireh M. The role of reactive oxygen species in immunopathogenesis of rheumatoid arthritis. Iran. J. Allergy Asthma Immunol. 2008;7:195–202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19052348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holers V.M., Banda N.K. Complement in the Initiation and Evolution of Rheumatoid Arthritis. Front. Immunol. 2018;9:1057. doi: 10.3389/fimmu.2018.01057.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2018.01057</ArticleId>
            <ArticleId IdType="pmc">PMC5985368</ArticleId>
            <ArticleId IdType="pubmed">29892280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paleolog E.M. Angiogenesis in rheumatoid arthritis. Arthritis Res. Ther. 2002;4:1–10. doi: 10.1186/AR575.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/AR575</ArticleId>
            <ArticleId IdType="pmc">PMC3240151</ArticleId>
            <ArticleId IdType="pubmed">12110126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elshabrawy H.A., Chen Z., Volin M.V., Ravella S., Virupannavar S., Shahrara S. The pathogenic role of angiogenesis in rheumatoid arthritis. Angiogenesis. 2015;18:433–448. doi: 10.1007/s10456-015-9477-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10456-015-9477-2</ArticleId>
            <ArticleId IdType="pmc">PMC4879881</ArticleId>
            <ArticleId IdType="pubmed">26198292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garrido-Trigo A., Salas A. Molecular structure and function of janus kinases: Implications for the Development of inhibitors. J. Crohn Colitis. 2020;14:713–724. doi: 10.1093/ecco-jcc/jjz206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ecco-jcc/jjz206</ArticleId>
            <ArticleId IdType="pmc">PMC7395311</ArticleId>
            <ArticleId IdType="pubmed">32083640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wasserman A. Diagnosis and management of rheumatoid arthritis. Am. Fam. Physician. 2011;84:1245–1252.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22150658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Radner H., Neogi T., Smolen J.S., Aletaha D. Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: A systematic literature review. Ann. Rheum. Dis. 2014;73:114–123. doi: 10.1136/annrheumdis-2013-203284.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2013-203284</ArticleId>
            <ArticleId IdType="pubmed">23592710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aletaha D., Neogi T., Silman A.J., Funovits J., Felson D.T., Bingham C.O., Birnbaum N.S., Burmester G.R., Bykerk V.P., Cohen M.D., et al.  Rheumatoid arthritis classification criteria: An American college of rheumatology/European league Against rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569–2581. doi: 10.1002/art.27584.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.27584</ArticleId>
            <ArticleId IdType="pubmed">20872595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jeffery R.C. Clinical features of rheumatoid arthritis. Medicine. 2014;42:231–236. doi: 10.1016/j.mpmed.2014.02.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mpmed.2014.02.011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aletaha D., Smolen J.S. Diagnosis and management of rheumatoid arthritis: A review. JAMA. 2018;320:1360–1372. doi: 10.1001/jama.2018.13103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2018.13103</ArticleId>
            <ArticleId IdType="pubmed">30285183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rasmussen A., Radfar L., Lewis D., Grundahl K., Stone D.U., Kaufman C.E., Rhodus N.L., Segal B., Wallace D.J., Weisman M.H., et al.  Previous diagnosis of Sjögren’s Syndrome as rheumatoid arthritis or systemic lupus erythematosus. Rheumatology. 2016;55:1195–1201. doi: 10.1093/rheumatology/kew023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/kew023</ArticleId>
            <ArticleId IdType="pmc">PMC6281033</ArticleId>
            <ArticleId IdType="pubmed">26998859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jevtic V., Lingg G. Differential diagnosis of rheumatoid and psoriatic arthritis at an early stage in the small hand and foot joints using magnetic resonance imaging. Handchir. Mikrochir. Plast. Chir. 2012;44:163–170. doi: 10.1055/S-0032-1321760.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/S-0032-1321760</ArticleId>
            <ArticleId IdType="pubmed">22833070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gutierrez M., Filippucci E., Salaffi F., di Geso L., Grassi W. Differential diagnosis between rheumatoid arthritis and psoriatic arthritis: The value of ultrasound findings at metacarpophalangeal joints level. Ann. Rheum. Dis. 2011;70:1111–1114. doi: 10.1136/ard.2010.147272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/ard.2010.147272</ArticleId>
            <ArticleId IdType="pubmed">21406459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arvikar S.L., Steere A.C. Diagnosis and treatment of lyme arthritis. Infect. Dis. Clin. N. Am. 2015;29:269–280. doi: 10.1016/j.idc.2015.02.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.idc.2015.02.004</ArticleId>
            <ArticleId IdType="pmc">PMC4443866</ArticleId>
            <ArticleId IdType="pubmed">25999223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Banal F., Dougados M., Combescure C., Gossec L. Sensitivity and specificity of the American College of Rheumatology 1987 criteria for the diagnosis of rheumatoid arthritis according to disease duration: A systematic literature review and meta-analysis. Ann. Rheum. Dis. 2009;68:1184–1191. doi: 10.1136/ard.2008.093187.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/ard.2008.093187</ArticleId>
            <ArticleId IdType="pubmed">18728049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luime J.J., Colin E.M., Hazes J.M.W., Lubberts E. Does anti-mutated citrullinated vimentin have additional value as a serological marker in the diagnostic and prognostic investigation of patients with rheumatoid arthritis? A systematic review. Ann. Rheum. Dis. 2010;69:337–344. doi: 10.1136/ard.2008.103283.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/ard.2008.103283</ArticleId>
            <ArticleId IdType="pubmed">19289382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maksymowych W.P., Naides S.J., Bykerk V., Siminovitch K.A., van Schaardenburg D., Boers M., Landewé R., van der Heijde D., Tak P.P., Genovese M.C., et al.  Serum 14-3-3η is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis. J. Rheumatol. 2014;41:2104–2113. doi: 10.3899/jrheum.131446.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3899/jrheum.131446</ArticleId>
            <ArticleId IdType="pubmed">25128504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeng T., Tan L. 14-3-3η protein: A promising biomarker for rheumatoid arthritis. Biomark. Med. 2018;12:917–925. doi: 10.2217/bmm-2017-0385.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/bmm-2017-0385</ArticleId>
            <ArticleId IdType="pubmed">30022679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brink M., Verheul M.K., Rönnelid J., Berglin E., Holmdahl R., Toes R.E., Klareskog L., Trouw L.A., Rantapää-Dahlqvist S. Anti-carbamylated protein antibodies in the pre-symptomatic phase of rheumatoid arthritis, their relationship with multiple anti-citrulline peptide antibodies and association with radiological damage. Arthritis Res. Ther. 2015;17:1–8. doi: 10.1186/s13075-015-0536-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13075-015-0536-2</ArticleId>
            <ArticleId IdType="pmc">PMC4350267</ArticleId>
            <ArticleId IdType="pubmed">25889922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mohamed S.R., Neseem N.O., Metwally S.S., El-Kady B.A. Diagnostic value and clinical significance of anti-carbamylated protein (anti-CarP) antibodies in Egyptian patients with rheumatoid arthritis. Egypt. Rheumatol. 2020;42:1–4. doi: 10.1016/j.ejr.2019.04.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejr.2019.04.004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi J., van de Stadt L.A., Levarht E.W.N., Huizinga T.W.J., Hamann D., van Schaardenburg D., Toes R.E.M., Trouw L.A. Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Ann. Rheum. Dis. 2014;73:780–783. doi: 10.1136/annrheumdis-2013-204154.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2013-204154</ArticleId>
            <ArticleId IdType="pubmed">24336334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Green M.J., Gough A.K.S., Devlin J., Smith J., Astin P., Taylor D., Emery P. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology. 2003;42:83–88. doi: 10.1093/rheumatology/keg037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/keg037</ArticleId>
            <ArticleId IdType="pubmed">12509618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jüngel A., Ospelt C., Lesch M., Thiel M., Sunyer T., Schorr O., Michel B.A., Gay R.E., Kolling C., Flory C., et al.  Effect of the oral application of a highly selective MMP-13 inhibitor in three different animal models of rheumatoid arthritis. Ann. Rheum. Dis. 2010;69:898–902. doi: 10.1136/ard.2008.106021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/ard.2008.106021</ArticleId>
            <ArticleId IdType="pmc">PMC2925150</ArticleId>
            <ArticleId IdType="pubmed">19497915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De la Rica L., Urquiza J.M., Gómez-Cabrero D., Islam A.B.M.M.K., López-Bigas N., Tegnér J., Toes R.E.M., Ballestar E. Identification of novel markers in rheumatoid arthritis through integrated analysis of DNA methylation and microRNA expression. J. Autoimmun. 2013;41:6–16. doi: 10.1016/j.jaut.2012.12.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaut.2012.12.005</ArticleId>
            <ArticleId IdType="pubmed">23306098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spierings J., van Eden W. Heat shock proteins and their immunomodulatory role in inflammatory arthritis. Rheumatology. 2017;56:198–208. doi: 10.1093/rheumatology/kew266.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/kew266</ArticleId>
            <ArticleId IdType="pubmed">27411479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mun S., Lee J., Park M., Shin J., Lim M.-K., Kang H.-G. Serum biomarker panel for the diagnosis of rheumatoid arthritis. Arthritis Res. Ther. 2021;23:1–10. doi: 10.1186/s13075-020-02405-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13075-020-02405-7</ArticleId>
            <ArticleId IdType="pmc">PMC7812661</ArticleId>
            <ArticleId IdType="pubmed">33461622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Väänänen T., Vuolteenaho K., Kautiainen H., Nieminen R., Möttönen T., Hannonen P., Korpela M., Kauppi M.J., Laiho K., Kaipiainen-Seppänen O., et al.  Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial. PLoS ONE. 2017;12:e0183294.  doi: 10.1371/journal.pone.0183294.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0183294</ArticleId>
            <ArticleId IdType="pmc">PMC5571914</ArticleId>
            <ArticleId IdType="pubmed">28841649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bas S., Perneger T.V., Seitz M., Tiercy J.-M., Roux-Lombard P., Guerne P.A. Diagnostic tests for rheumatoid arthritis: Comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology. 2002;41:809–814. doi: 10.1093/rheumatology/41.7.809.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/41.7.809</ArticleId>
            <ArticleId IdType="pubmed">12096232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albrecht K., Zink A. Poor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: A review of data from randomized clinical trials and cohort studies. Arthritis Res. Ther. 2017;19:1–8. doi: 10.1186/s13075-017-1266-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13075-017-1266-4</ArticleId>
            <ArticleId IdType="pmc">PMC5364634</ArticleId>
            <ArticleId IdType="pubmed">28335797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marotta A., Maksymowych W.P. SAT0070 levels of 14-3-3eta predict good eular response to anti-TNF treatment in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2014;73:615–616. doi: 10.1136/annrheumdis-2014-eular.3426.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2014-eular.3426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morozzi G., Fabbroni M., Bellisai F., Cucini S., Simpatico A., Galeazzi M. Low serum level of COMP, a cartilage turnover marker, predicts rapid and high ACR70 response to adalimumab therapy in rheumatoid arthritis. Clin. Rheumatol. 2007;26:1335–1338. doi: 10.1007/s10067-006-0520-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10067-006-0520-y</ArticleId>
            <ArticleId IdType="pubmed">17285224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fabris M., de Vita S., Blasone N., Visentini D., Pezzarini E., Pontarini E., Fabro C., Quartuccio L., Mazzolini S., Curcio F., et al.  Serum levels of anti-CCP antibodies, anti-MCV antibodies and RF IgA in the follow-up of patients with rheumatoid arthritis treated with rituximab. Autoimmun. Highlights. 2010;1:87–94. doi: 10.1007/s13317-010-0013-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13317-010-0013-5</ArticleId>
            <ArticleId IdType="pmc">PMC4389048</ArticleId>
            <ArticleId IdType="pubmed">26000112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Isgren A., Forslind K., Erlandsson M., Axelsson C., Andersson S., Lund A., Bokarewa M. High survivin levels predict poor clinical response to infliximab treatment in patients with rheumatoid arthritis. Semin. Arthritis Rheum. 2012;41:652–657. doi: 10.1016/j.semarthrit.2011.08.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semarthrit.2011.08.005</ArticleId>
            <ArticleId IdType="pubmed">22035627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kgoebane K., Ally M.M.T.M., Duim-Beytell M.C., Suleman F.E. The role of imaging in rheumatoid arthritis. SA J. Radiol. 2018;22:1316–1322. doi: 10.4102/sajr.v22i1.1316.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4102/sajr.v22i1.1316</ArticleId>
            <ArticleId IdType="pmc">PMC6837821</ArticleId>
            <ArticleId IdType="pubmed">31754498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Døhn U.M., Ejbjerg B.J., Hasselquist M., Narvestad E., Møller J., Thomsen H.S., Østergaard M. Detection of bone erosions in rheumatoid arthritis wrist joints with magnetic resonance imaging, computed tomography and radiography. Arthritis Res. Ther. 2008;10:1–8. doi: 10.1186/ar2378.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/ar2378</ArticleId>
            <ArticleId IdType="pmc">PMC2374457</ArticleId>
            <ArticleId IdType="pubmed">18307764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salaffi F., Gutierrez M., Carotti M. Ultrasound versus conventional radiography in the assessment of bone erosions in rheumatoid arthritis. Clin. Exp. Rheumatol. 2014;32:85–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24528649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vyas S., Bhalla A.S., Ranjan P., Kumar S., Kumar U., Gupta A.K. Rheumatoid arthritis revisited—Advanced imaging review. Polish J. Radiol. 2016;81:629–635. doi: 10.12659/PJR.899317.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.12659/PJR.899317</ArticleId>
            <ArticleId IdType="pmc">PMC5223782</ArticleId>
            <ArticleId IdType="pubmed">28105245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Šenolt L., Grassi W., Szodoray P. Laboratory biomarkers or imaging in the diagnostics of rheumatoid arthritis? BMC Med. 2014;12:49.  doi: 10.1186/1741-7015-12-49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1741-7015-12-49</ArticleId>
            <ArticleId IdType="pmc">PMC3984686</ArticleId>
            <ArticleId IdType="pubmed">24642071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wakefield R.J., Gibbon W.W., Conaghan P.G., O’Connor P., McGonagle D., Pease C., Green M.J., Veale D.J., Isaacs J.D., Emery P. The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis: A comparison with conventional radiography. Arthritis Rheum. 2000;43:2762–2770. doi: 10.1002/1529-0131(200012)43:12&lt;2762::AID-ANR16&gt;3.0.CO;2-#.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1529-0131(200012)43:12&lt;2762::AID-ANR16&gt;3.0.CO;2-#</ArticleId>
            <ArticleId IdType="pubmed">11145034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Døhn U.M., Ejbjerg B.J., Hasselquist M., Narvestad E., Court-Payen M., Szkudlarek M., Møller J., Thomsen H., Ostergaard M. Rheumatoid arthritis bone erosion volumes on CT and MRI: Reliability and correlations with erosion scoRes. on CT, MRI and radiography. Ann. Rheum. Dis. 2007;66:1388–1392. doi: 10.1136/ard.2007.072520.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/ard.2007.072520</ArticleId>
            <ArticleId IdType="pmc">PMC1994287</ArticleId>
            <ArticleId IdType="pubmed">17606464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Regensburger A., Rech J., Englbrecht M., Finzel S., Kraus S., Hecht K., Kleyer A., Haschka J., Hueber A.J., Cavallaro A., et al.  A comparative analysis of magnetic resonance imaging and high-resolution peripheral quantitative computed tomography of the hand for the detection of erosion repair in rheumatoid arthritis. Rheumatology. 2015;54:1573–1581. doi: 10.1093/rheumatology/kev031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/kev031</ArticleId>
            <ArticleId IdType="pubmed">25832611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Døhn U.M., Ejbjerg B.J., Court-Payen M., Hasselquist M., Narvestad E., Szkudlarek M., Møller J.M., Thomsen H.S., Østergaard M. Are bone erosions detected by magnetic resonance imaging and ultrasonography true erosions? A comparison with computed tomography in rheumatoid arthritis metacarpophalangeal joints. Arthritis Res. Ther. 2006;8:1–9. doi: 10.1186/ar1995.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/ar1995</ArticleId>
            <ArticleId IdType="pmc">PMC1779369</ArticleId>
            <ArticleId IdType="pubmed">16848914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wouters F., Matthijssen X., Boeters D.M., Ten Brinck R.M., van der Helm-Van Mil A., Niemantsverdriet E. Do magnetic resonance imaging-detected erosions predict progression to rheumatoid arthritis in patients presenting with clinically suspect arthralgia? A longitudinal study. Scand. J. Rheumatol. 2020;49:461–467. doi: 10.1080/03009742.2020.1737221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/03009742.2020.1737221</ArticleId>
            <ArticleId IdType="pmc">PMC7116362</ArticleId>
            <ArticleId IdType="pubmed">32484376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giles J.T. Extra-articular manifestations and comorbidity in rheumatoid arthritis: Potential impact of pre–rheumatoid arthritis prevention. Clin. Ther. 2019;41:1246–1255. doi: 10.1016/j.clinthera.2019.04.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clinthera.2019.04.018</ArticleId>
            <ArticleId IdType="pubmed">31196641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turesson C., O’Fallon W.M., Crowson C.S., Gabriel S.E., Matteson E.L. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J. Rheumatol. 2002;29:62–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11824973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cimmino M.A., Salvarani C., Macchioni P., Montecucco C., Fossaluzza V., Mascia M.T., Punzi L., Davoli C., Filippini D., Numo R. Extra-articular manifestations in 587 Italian patients with rheumatoid arthritis. Rheumatol. Int. 2000;19:213–217. doi: 10.1007/PL00006853.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/PL00006853</ArticleId>
            <ArticleId IdType="pubmed">11063290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roman M.J., Salmon J.E. Cardiovascular manifestations of rheumatologic diseases. Circulation. 2007;116:2346–2355. doi: 10.1161/CIRCULATIONAHA.106.678334.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.106.678334</ArticleId>
            <ArticleId IdType="pubmed">17998471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baghdadi L.R., Woodman R.J., Shanahan E.M., Mangoni A.A. The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: A systematic review and meta-analysis. PLoS ONE. 2015;10:e0117952.  doi: 10.1371/journal.pone.0117952.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0117952</ArticleId>
            <ArticleId IdType="pmc">PMC4331556</ArticleId>
            <ArticleId IdType="pubmed">25689371</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Avina-Zubieta J.A., Thomas J., Sadatsafavi M., Lehman A.J., Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: A meta-analysis of observational studies. Ann. Rheum. Dis. 2012;71:1524–1529. doi: 10.1136/annrheumdis-2011-200726.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2011-200726</ArticleId>
            <ArticleId IdType="pubmed">22425941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gonzalez-Juanatey C., Testa A., Garcia-Castelo A., Garcia-Porrua C., Llorca J., Ollier W.E.R., Gonzalez-Gay M.A. Echocardiographic and Doppler findings in long-term treated rheumatoid arthritis patients without clinically evident cardiovascular disease. Semin. Arthritis Rheum. 2004;33:231–238. doi: 10.1053/j.semarthrit.2003.09.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.semarthrit.2003.09.011</ArticleId>
            <ArticleId IdType="pubmed">14978661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nadkar M.Y., Agarwal R., Samant R.S., Chhugani S.J., Idgunji S.J., Iyer S., Borges N.E. Neuropathy in rheumatoid arthritis. J. Assoc. Physicians India. 2001;49:217–220.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11225133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Y., Xu W., Yang H., Shao M., Xu S., Deng J., Gao X., Liu H., Shuai Z., Xu S., et al.  Serum levels of hepcidin in rheumatoid arthritis and its correlation with disease activity and anemia: A Meta-analysis. Immunol. Investig. 2021;50:243–258. doi: 10.1080/08820139.2020.1742731.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/08820139.2020.1742731</ArticleId>
            <ArticleId IdType="pubmed">32216485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chavalitdhamrong D., Molovic-Kokovic A., Iliev A. Felty’s Syndrome as an initial presentation of rheumatoid arthritis: A case report. Cases J. 2009;2:1–3. doi: 10.1186/1757-1626-2-206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1757-1626-2-206</ArticleId>
            <ArticleId IdType="pmc">PMC2783155</ArticleId>
            <ArticleId IdType="pubmed">19946450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taylor P.C., Atzeni F., Balsa A., Gossec L., Müller-Ladner U., Pope J. The key comorbidities in patients with rheumatoid arthritis: A Narrative review. J. Clin. Med. 2021;10:509.  doi: 10.3390/jcm10030509.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/jcm10030509</ArticleId>
            <ArticleId IdType="pmc">PMC7867048</ArticleId>
            <ArticleId IdType="pubmed">33535498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haddani F., Guich A., Youssoufi T., Boudhar E., Abouqal R., Achemlal L., Allali F., Bahiri R., Bouchti E., Maghraoui E., et al.  Comorbidities in rheumatoid arthritis: The RBSMR study. Int. J. Clin. Rheumtol. 2020;15:1–10. doi: 10.37532/1758-4272.2020.15(1).10-14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.37532/1758-4272.2020.15(1).10-14</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roubille C., Richer V., Starnino T., McCourt C., McFarlane A., Fleming P., Siu S., Kraft J., Lynde C., Pope J., et al.  The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: A systematic review and meta-analysis. Ann. Rheum. Dis. 2015;74:480–489. doi: 10.1136/annrheumdis-2014-206624.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2014-206624</ArticleId>
            <ArticleId IdType="pmc">PMC4345910</ArticleId>
            <ArticleId IdType="pubmed">25561362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Behl T., Kaur I., Sehgal A., Zengin G., Brisc C., Brisc M.C., Munteanu M.A., Nistor-Cseppento D.C., Bungau S. The lipid paradox as a metabolic checkpoint and its therapeutic significance in ameliorating the associated cardiovascular risks in rheumatoid arthritis patients. Int. J. Mol. Sci. 2020;21:9505.  doi: 10.3390/ijms21249505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms21249505</ArticleId>
            <ArticleId IdType="pmc">PMC7764917</ArticleId>
            <ArticleId IdType="pubmed">33327502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vicente G., Pereira I., de Castro G., da Mota L., Carnieletto A., de Souza D., da Gama F., Santos A., de Albuquerque C., Bértolo M., et al.  Cardiovascular risk comorbidities in rheumatoid arthritis patients and the use of anti-rheumatic drugs: A cross-sectional real-life study. Adv. Rheumatol. 2021;61:38. doi: 10.1186/s42358-021-00186-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s42358-021-00186-4</ArticleId>
            <ArticleId IdType="pubmed">34172097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agca R., Heslinga S.C., Rollefstad S., Heslinga M., McInnes I.B., Peters M.J.L., Kvien T.K., Dougados M., Radner H., Atzeni F., et al.  EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann. Rheum. Dis. 2017;76:17–28. doi: 10.1136/annrheumdis-2016-209775.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2016-209775</ArticleId>
            <ArticleId IdType="pubmed">27697765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daïen C.I., Tubery A., du Cailar G., Mura T., Roubille F., Morel J., Bousquet J., Fesler P., Combe B. Application of the 2015/2016 EULAR recommendations for cardiovascular risk in daily practice: Data from an observational study. Ann. Rheum. Dis. 2018;77:625–626. doi: 10.1136/annrheumdis-2017-211074.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2017-211074</ArticleId>
            <ArticleId IdType="pubmed">28478400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soulaidopoulos S., Nikiphorou E., Dimitroulas T., Kitas G.D. The role of statins in disease modification and cardiovascular risk in rheumatoid arthritis. Front. Med. 2018;5:24. doi: 10.3389/fmed.2018.00024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fmed.2018.00024</ArticleId>
            <ArticleId IdType="pmc">PMC5809441</ArticleId>
            <ArticleId IdType="pubmed">29473041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baillet A., Gossec L., Carmona L., de Wit M., van Eijk-Hustings Y., Bertheussen H., Alison K., Toft M., Kouloumas M., Ferreira R.J.O., et al.  Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: A EULAR initiative. Ann. Rheum. Dis. 2016;75:965–973. doi: 10.1136/annrheumdis-2016-209233.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2016-209233</ArticleId>
            <ArticleId IdType="pubmed">26984008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Assen S., Agmon-Levin N., Elkayam O., Cervera R., Doran M.F., Dougados M., Emery P., Geborek P., Ioannidis J.P.A., Jayne D.R.W., et al.  EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann. Rheum. Dis. 2011;70:414–422. doi: 10.1136/ard.2010.137216.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/ard.2010.137216</ArticleId>
            <ArticleId IdType="pubmed">21131643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raghu G., Collard H.R., Egan J.J., Martinez F.J., Behr J., Brown K.K., Colby T.V., Cordier J.-F., Flaherty K.R., Lasky J.A., et al.  An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2012;183:788–824. doi: 10.1164/rccm.2009-040GL.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1164/rccm.2009-040GL</ArticleId>
            <ArticleId IdType="pmc">PMC5450933</ArticleId>
            <ArticleId IdType="pubmed">21471066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bluett J., Jani M., Symmons D.P.M. Practical management of respiratory comorbidities in patients with rheumatoid arthritis. Rheumatol. Ther. 2017;4:309–332. doi: 10.1007/s40744-017-0071-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40744-017-0071-5</ArticleId>
            <ArticleId IdType="pmc">PMC5696283</ArticleId>
            <ArticleId IdType="pubmed">28808949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loud J., Murphy J. Cancer screening and early detection in the 21st century. Semin. Oncol. Nurs. 2017;33:121–128. doi: 10.1016/j.soncn.2017.02.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.soncn.2017.02.002</ArticleId>
            <ArticleId IdType="pmc">PMC5467686</ArticleId>
            <ArticleId IdType="pubmed">28343835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roubille C., Richer V., Starnino T., McCourt C., McFarlane A., Fleming P., Siu S., Kraft J., Lynde C., Pope J., et al.  Evidence-based recommendations for the management of comorbidities in rheumatoid arthritis, psoriasis, and psoriatic arthritis: Expert opinion of the canadian dermatology-rheumatology comorbidity initiative. J. Rheumatol. 2015;42:1767–1780. doi: 10.3899/jrheum.141112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3899/jrheum.141112</ArticleId>
            <ArticleId IdType="pubmed">26178281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carmona L., González-Álvaro I., Balsa A., Belmonte M.A., Tena X., Sanmartí R., Group E.S. Rheumatoid arthritis in Spain: Occurrence of extra-articular manifestations and estimates of disease severity. Ann. Rheum. Dis. 2003;62:897–900. doi: 10.1136/ard.62.9.897.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/ard.62.9.897</ArticleId>
            <ArticleId IdType="pmc">PMC1754657</ArticleId>
            <ArticleId IdType="pubmed">12922967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Young A., Koduri G. Extra-articular manifestations and complications of rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol. 2007;21:907–927. doi: 10.1016/j.berh.2007.05.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.berh.2007.05.007</ArticleId>
            <ArticleId IdType="pubmed">17870035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fraenkel L., Bathon J.M., England B.R., St. Clair E.W., Arayssi T., Carandang K., Deane K.D., Genovese M., Huston K.K., Kerr G., et al.  American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73:924–939. doi: 10.1002/acr.24596.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/acr.24596</ArticleId>
            <ArticleId IdType="pubmed">34101387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deane K. Can rheumatoid arthritis be prevented? Best Pract. Res. Clin. Rheumatol. 2013;27:467–485. doi: 10.1016/j.berh.2013.09.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.berh.2013.09.002</ArticleId>
            <ArticleId IdType="pmc">PMC3926812</ArticleId>
            <ArticleId IdType="pubmed">24315049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klareskog L., Gregersen P.K., Huizinga T.W.J. Prevention of autoimmune rheumatic disease: State of the art and future perspectives. Ann. Rheum. Dis. 2010;69:2062–2066. doi: 10.1136/ard.2010.142109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/ard.2010.142109</ArticleId>
            <ArticleId IdType="pubmed">21097657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larrieu T., Layé S. Food for mood: Relevance of nutritional omega-3 fatty acids for depression and anxiety. Front. Physiol. 2018;9:1047. doi: 10.3389/fphys.2018.01047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphys.2018.01047</ArticleId>
            <ArticleId IdType="pmc">PMC6087749</ArticleId>
            <ArticleId IdType="pubmed">30127751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liao Y., Xie B., Zhang H., He Q., Guo L., Subramanieapillai M., Fan B., Lu C., McIntyre R.S. Efficacy of omega-3 PUFAs in depression: A meta-analysis. Transl. Psychiatry. 2019;9:190. doi: 10.1038/s41398-019-0515-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41398-019-0515-5</ArticleId>
            <ArticleId IdType="pmc">PMC6683166</ArticleId>
            <ArticleId IdType="pubmed">31383846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hallahan B., Ryan T., Hibbeln J.R., Murray I.T., Glynn S., Ramsden C.E., SanGiovanni J.P., Davis J.M. Efficacy of omega-3 highly unsaturated fatty acids in the treatment of depression. Br. J. Psychiatry. 2016;209:192–201. doi: 10.1192/bjp.bp.114.160242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1192/bjp.bp.114.160242</ArticleId>
            <ArticleId IdType="pubmed">27103682</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sublette M.E., Ellis S.P., Geant A.L., Mann J.J. Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J. Clin. Psychiatry. 2011;72:1577–1584. doi: 10.4088/JCP.10m06634.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4088/JCP.10m06634</ArticleId>
            <ArticleId IdType="pmc">PMC3534764</ArticleId>
            <ArticleId IdType="pubmed">21939614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuan-Pin S., Ping-Tao T., Pao-Yen L., Ryo O., Tien-Yu C., Yen-Wen C., Yutaka J.M. Association of use of omega-3 polyunsaturated fatty acids with changes in severity of anxiety symptoms: A systematic review and meta-analysis. JAMA Netw. Open. 2018;1:e182327. doi: 10.1001/JAMANETWORKOPEN.2018.2327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/JAMANETWORKOPEN.2018.2327</ArticleId>
            <ArticleId IdType="pmc">PMC6324500</ArticleId>
            <ArticleId IdType="pubmed">30646157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang C.-K., Chen P.-K., Chen C.-C., Chang S.-H., Chen C.-H., Chen D.-Y. Increased levels of omega-3 fatty acids and DHA are linked to pain reduction in rheumatoid arthritis patients treated with janus kinase inhibitors. Nutrients. 2021;13:3050.  doi: 10.3390/nu13093050.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/nu13093050</ArticleId>
            <ArticleId IdType="pmc">PMC8465317</ArticleId>
            <ArticleId IdType="pubmed">34578928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cramp F. The role of non-pharmacological interventions in the management of rheumatoid-arthritis-related fatigue. Rheumatology. 2019;58:22–28. doi: 10.1093/rheumatology/kez310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/kez310</ArticleId>
            <ArticleId IdType="pmc">PMC6827265</ArticleId>
            <ArticleId IdType="pubmed">31682276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hewlett S., Chalder T., Choy E., Cramp F., Davis B., Dures E., Nicholls C., Kirwan J. Fatigue in rheumatoid arthritis: Time for a conceptual model. Rheumatology. 2011;50:1004–1006. doi: 10.1093/rheumatology/keq282.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/keq282</ArticleId>
            <ArticleId IdType="pubmed">20819797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steultjens E.M.J., Dekker J., Bouter L.M., Schaardenburg D., van Kuyk M.A.H., van den Ende C.H. Occupational therapy for rheumatoid arthritis: A systematic review. Arthritis Care Res. 2002;47:672–685. doi: 10.1002/art.10801.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.10801</ArticleId>
            <ArticleId IdType="pubmed">12522844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trieb K., Hofstaetter S.G. Treatment strategies in surgery for rheumatoid arthritis. Eur. J. Radiol. 2009;71:204–210. doi: 10.1016/j.ejrad.2009.04.050.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejrad.2009.04.050</ArticleId>
            <ArticleId IdType="pubmed">19577394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin A., Chopra R., Nicassio P. Nonpharmacologic pain management in inflammatory arthritis. Rheum. Dis. Clin. North Am. 2021;47:277–295. doi: 10.1016/j.rdc.2020.12.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.rdc.2020.12.009</ArticleId>
            <ArticleId IdType="pubmed">33781495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smolen J.S., Landewé R.B.M., Bijlsma J.W.J., Burmester G.R., Dougados M., Kerschbaumer A., McInnes I.B., Sepriano A., van Vollenhoven R.F., de Wit M., et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann. Rheum. Dis. 2020;79:685–699. doi: 10.1136/annrheumdis-2019-216655.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2019-216655</ArticleId>
            <ArticleId IdType="pubmed">31969328</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Whittle S.L., Colebatch A.N., Buchbinder R., Edwards C.J., Adams K., Englbrecht M., Hazlewood G., Marks J.L., Radner H., Ramiro S., et al.  Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: Integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative. Rheumatology. 2012;51:1416–1425. doi: 10.1093/rheumatology/kes032.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/kes032</ArticleId>
            <ArticleId IdType="pmc">PMC3397467</ArticleId>
            <ArticleId IdType="pubmed">22447886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crofford L.J. Use of NSAIDs in treating patients with arthritis. Arthritis Res. Ther. 2013;15:S2. doi: 10.1186/ar4174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/ar4174</ArticleId>
            <ArticleId IdType="pmc">PMC3891482</ArticleId>
            <ArticleId IdType="pubmed">24267197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hochberg M.C. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis. Semin. Arthritis Rheum. 2002;32:4–14. doi: 10.1053/sarh.2002.37215.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/sarh.2002.37215</ArticleId>
            <ArticleId IdType="pubmed">12528069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bullock J., Rizvi S.A.A., Saleh A.M., Ahmed S.S., Do D.P., Ansari R.A., Ahmed J. Rheumatoid arthritis: A brief overview of the treatment. Med. Princ. Pract. 2019;27:501–507. doi: 10.1159/000493390.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000493390</ArticleId>
            <ArticleId IdType="pmc">PMC6422329</ArticleId>
            <ArticleId IdType="pubmed">30173215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hua C., Buttgereit F., Combe B. Glucocorticoids in rheumatoid arthritis: Current status and future studies. RMD Open. 2020;6:e000536. doi: 10.1136/rmdopen-2017-000536.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/rmdopen-2017-000536</ArticleId>
            <ArticleId IdType="pmc">PMC7046968</ArticleId>
            <ArticleId IdType="pubmed">31958273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Monti S., Klersy C., Gorla R., Sarzi-Puttini P., Atzeni F., Pellerito R., Fusaro E., Paolazzi G., Rocchetta P.A., Favalli E.G., et al.  Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: Real-life data from the Italian LORHEN registry. Clin. Rheumatol. 2017;36:753–761. doi: 10.1007/s10067-016-3528-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10067-016-3528-y</ArticleId>
            <ArticleId IdType="pubmed">28058538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bywall K.S., Kihlbom U., Hansson M., Falahee M., Raza K., Baecklund E., Veldwijk J. Patient preferences on rheumatoid arthritis second-line treatment: A discrete choice experiment of Swedish patients. Arthritis Res. Ther. 2020;22:1–10. doi: 10.1186/s13075-020-02391-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13075-020-02391-w</ArticleId>
            <ArticleId IdType="pmc">PMC7749986</ArticleId>
            <ArticleId IdType="pubmed">33341117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yazici Y. Long-term safety of methotrexate in the treatment of rheumatoid arthritis. Clin. Exp. Rheumatol. 2010;28:65–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21044436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alfaro-Lara R., Espinosa-Ortega H.F., Arce-Salinas C.A. Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis. Reumatol. Clín. 2019;15:133–139. doi: 10.1016/j.reuma.2017.07.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.reuma.2017.07.020</ArticleId>
            <ArticleId IdType="pubmed">28867467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W., Zhou H., Liu L. Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review. Eur. J. Med. Chem. 2018;158:502–516. doi: 10.1016/j.ejmech.2018.09.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejmech.2018.09.027</ArticleId>
            <ArticleId IdType="pubmed">30243154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalden J.R., Schattenkirchner M., Sörensen H., Emery P., Deighton C., Rozman B., Breedveld F. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: A five-year followup study. Arthritis Rheum. 2003;48:1513–1520. doi: 10.1002/art.11015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.11015</ArticleId>
            <ArticleId IdType="pubmed">12794818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Das S.K., Pareek A., Mathur D.S., Wanchu A., Srivastava R., Agarwal G.G., Chauhan R.S. Efficacy and Safety of hydroxychloroquine sulphate in rheumatoid arthritis: A randomized, double-blind, placebo controlled clinical trial—An Indian experience. Curr. Med. Res. Opin. 2007;23:2227–2234. doi: 10.1185/030079907X219634.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1185/030079907X219634</ArticleId>
            <ArticleId IdType="pubmed">17692155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Da Silva J.C., Mariz H.A., da Rocha Júnior L.F., de Oliveira P.S.S., Dantas A.T., Duarte A.L.B.P., da Pitta I.R., Galdino S.L., da Pitta M.G.R. Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients. Clinics. 2013;68:766–771. doi: 10.6061/clinics/2013(06)07.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.6061/clinics/2013(06)07</ArticleId>
            <ArticleId IdType="pmc">PMC3674253</ArticleId>
            <ArticleId IdType="pubmed">23778483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dogra A., Sharma A., Mandal U.K., Kotwal P., Bhatt S., Nandi U. Liquid chromatography based methods for analysis of disease-modifying antirheumatic drugs (DMARDs) in biological matrices. Crit. Rev. Anal. Chem. 2019;49:224–242. doi: 10.1080/10408347.2018.1503943.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/10408347.2018.1503943</ArticleId>
            <ArticleId IdType="pubmed">30669854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Vollenhoven R.F. New therapeutic approaches in rheumatoid arthritis. Presse Med. 2016;45:179–192. doi: 10.1016/j.lpm.2016.05.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lpm.2016.05.004</ArticleId>
            <ArticleId IdType="pubmed">27242206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fassmer A.M., Garbe E., Schmedt N. Frequency and trends of disease-modifying antirheumatic drug (DMARD) use in Germany. Pharmacol. Res. Perspect. 2016;4:e00254. doi: 10.1002/prp2.254.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/prp2.254</ArticleId>
            <ArticleId IdType="pmc">PMC5045940</ArticleId>
            <ArticleId IdType="pubmed">27713825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Curtis J.R., Singh J.A. The use of biologics in rheumatoid arthritis: Current and emerging paradigms of care. Clin. Ther. 2011;33:679–707. doi: 10.1016/j.clinthera.2011.05.044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clinthera.2011.05.044</ArticleId>
            <ArticleId IdType="pmc">PMC3707489</ArticleId>
            <ArticleId IdType="pubmed">21704234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van de Putte L.B.A., Atkins C., Malaise M., Sany J., Russell A.S., van Riel P.L.C.M., Settas L., Bijlsma J.W., Todesco S., Dougados M., et al.  Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann. Rheum. Dis. 2004;63:508–516. doi: 10.1136/ard.2003.013052.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/ard.2003.013052</ArticleId>
            <ArticleId IdType="pmc">PMC1755008</ArticleId>
            <ArticleId IdType="pubmed">15082480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275–2285. doi: 10.1001/jama.295.19.2275.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.295.19.2275</ArticleId>
            <ArticleId IdType="pubmed">16705109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sartori N.S., Picon P., Papke A., Neyeloff J.L., da Silva Chakr R.M. A population-based study of tuberculosis incidence among rheumatic disease patients under anti-TNF treatment. PLoS ONE. 2019;14:e0224963.  doi: 10.1371/journal.pone.0224963.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0224963</ArticleId>
            <ArticleId IdType="pmc">PMC6886754</ArticleId>
            <ArticleId IdType="pubmed">31790428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huizinga T.W.J., Torii Y., Muniz R. Adalimumab biosimilars in the treatment of rheumatoid arthritis: A systematic review of the evidence for biosimilarity. Rheumatol. Ther. 2021;8:41–61. doi: 10.1007/s40744-020-00259-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40744-020-00259-8</ArticleId>
            <ArticleId IdType="pmc">PMC7991039</ArticleId>
            <ArticleId IdType="pubmed">33263165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao S., Mysler E., Moots R. Etanercept for the treatment of rheumatoid arthritis. Immunotherapy. 2018;10:433–445. doi: 10.2217/imt-2017-0155.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/imt-2017-0155</ArticleId>
            <ArticleId IdType="pubmed">29482402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klareskog L., Gaubitz M., Rodriguez-Valverde V., Malaise M., Dougados M., Wajdula J. A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs. Ann. Rheum. Dis. 2006;65:1578–1584. doi: 10.1136/ard.2005.038349.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/ard.2005.038349</ArticleId>
            <ArticleId IdType="pmc">PMC1798461</ArticleId>
            <ArticleId IdType="pubmed">16540554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh J.A., Christensen R., Wells G.A., Suarez-Almazor M.E., Buchbinder R., Lopez-Olivo M.A., Ghogomu E.T., Tugwell P. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: A Cochrane overview. Can. Med. Assoc. J. 2009;181:787–796. doi: 10.1503/cmaj.091391.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1503/cmaj.091391</ArticleId>
            <ArticleId IdType="pmc">PMC2780484</ArticleId>
            <ArticleId IdType="pubmed">19884297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jørgensen T., Turesson C., Kapetanovic M., Englund M., Turkiewicz A., Christensen R., Bliddal H., Geborek P., Kristensen L. EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registry. PLoS ONE. 2017;12:e0169946.  doi: 10.1371/journal.pone.0169946.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0169946</ArticleId>
            <ArticleId IdType="pmc">PMC5289416</ArticleId>
            <ArticleId IdType="pubmed">28151971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weinblatt M.E., Bathon J.M., Kremer J.M., Fleischmann R.M., Schiff M.H., Martin R.W., Baumgartner S.W., Park G.S., Mancini E.L., Genovese M.C. Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis. Arthritis Care Res. 2011;63:373–382. doi: 10.1002/ACR.20372.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ACR.20372</ArticleId>
            <ArticleId IdType="pubmed">20957659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Umeda M., Koga T., Ichinose K., Takatani A., Igawa T., Shimizu T., Fukui S., Nishino A., Horai Y., Hirai Y., et al.  Efficacy of infliximab as a switched biologic in rheumatoid arthritis patients in daily clinical practice. Immunol. Med. 2018;41:181–186. doi: 10.1080/25785826.2018.1542942.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/25785826.2018.1542942</ArticleId>
            <ArticleId IdType="pubmed">30632931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kameda H., Uechi E., Atsumi T., Abud-Mendoza C., Kamei K., Matsumoto T., de Leon D.P., Rehman M.I., Zhang M., Radominski S.C. A comparative study of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderate to severe active rheumatoid arthritis: A subgroup analysis. Int. J. Rheum. Dis. 2020;23:876–881. doi: 10.1111/1756-185X.13846.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/1756-185X.13846</ArticleId>
            <ArticleId IdType="pmc">PMC7496806</ArticleId>
            <ArticleId IdType="pubmed">32476277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonek K., Roszkowski L., Massalska M., Maslinski W., Ciechomska M. Biologic drugs for rheumatoid arthritis in the context of biosimilars, genetics, epigenetics and COVID-19 treatment. Cells. 2021;10:323.  doi: 10.3390/cells10020323.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cells10020323</ArticleId>
            <ArticleId IdType="pmc">PMC7914976</ArticleId>
            <ArticleId IdType="pubmed">33557301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mariette X., Förger F., Abraham B., Flynn A.D., Moltó A., Flipo R.-M., van Tubergen A., Shaughnessy L., Simpson J., Teil M., et al.  Lack of placental transfer of certolizumab pegol during pregnancy: Results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann. Rheum. Dis. 2018;77:228–233. doi: 10.1136/annrheumdis-2017-212196.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2017-212196</ArticleId>
            <ArticleId IdType="pmc">PMC5867410</ArticleId>
            <ArticleId IdType="pubmed">29030361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schiff M., Keiserman M., Codding C., Songcharoen S., Berman A., Nayiager S., Saldate C., Li T., Aranda R., Becker J.-C., et al.  Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: A phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann. Rheum. Dis. 2008;67:1096–1103. doi: 10.1136/ard.2007.080002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/ard.2007.080002</ArticleId>
            <ArticleId IdType="pmc">PMC2564802</ArticleId>
            <ArticleId IdType="pubmed">18055472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Germay S., Bagheri H., Despas F., Rousseau V., Montastruc F. Abatacept in rheumatoid arthritis and the risk of cancer: A world observational post-marketing study. Rheumatology. 2020;59:2360–2367. doi: 10.1093/rheumatology/kez604.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/kez604</ArticleId>
            <ArticleId IdType="pubmed">31880308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burmester G.R., Choy E., Kivitz A., Ogata A., Bao M., Nomura A., Lacey S., Pei J., Reiss W., Pethoe-Schramm A., et al.  Low immunogenicity of tocilizumab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2017;76:1078–1085. doi: 10.1136/annrheumdis-2016-210297.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2016-210297</ArticleId>
            <ArticleId IdType="pubmed">28007755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gabay C., Emery P., van Vollenhoven R., Dikranian A., Alten R., Pavelka K., Klearman M., Musselman D., Agarwal S., Green J., et al.  Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): A randomised, double-blind, controlled phase 4 trial. Lancet. 2013;381:1541–1550. doi: 10.1016/S0140-6736(13)60250-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(13)60250-0</ArticleId>
            <ArticleId IdType="pubmed">23515142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salliot C., Dougados M., Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: Meta-analyses of randomised placebo-controlled trials. Ann. Rheum. Dis. 2009;68:25–32. doi: 10.1136/ard.2007.083188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/ard.2007.083188</ArticleId>
            <ArticleId IdType="pmc">PMC2596305</ArticleId>
            <ArticleId IdType="pubmed">18203761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wendler J., Burmester G.R., Sörensen H., Krause A., Richter C., Tony H.P., Rubbert-Roth A., Bartz-Bazzanella P., Wassenberg S., Haug-Rost I., et al.  Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): Six-year results from a prospective, multicentre, non-interventional study in 2,484 patients. Arthritis Res. Ther. 2014;16:1–9. doi: 10.1186/ar4521.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/ar4521</ArticleId>
            <ArticleId IdType="pmc">PMC4060207</ArticleId>
            <ArticleId IdType="pubmed">24670196</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sánchez-Piedra C., Sueiro-Delgado D., García-González J., Ros-Vilamajo I., Prior-Español A., Moreno-Ramos M.J., Garcia-Magallon B., Calvo-Gutiérrez J., Perez-Vera Y., Martín-Domenech R., et al.  Changes in the use patterns of bDMARDs in patients with rheumatic diseases over the past 13 years. Sci. Rep. 2021;11:15051. doi: 10.1038/s41598-021-94504-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-021-94504-x</ArticleId>
            <ArticleId IdType="pmc">PMC8302725</ArticleId>
            <ArticleId IdType="pubmed">34302036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamaoka K. Janus kinase inhibitors for rheumatoid arthritis. Curr. Opin. Chem. Biol. 2016;32:29–33. doi: 10.1016/j.cbpa.2016.03.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cbpa.2016.03.006</ArticleId>
            <ArticleId IdType="pubmed">26994322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Angelini J., Talotta R., Roncato R., Fornasier G., Barbiero G., Cin L.D., Brancati S., Scaglione F. JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future. Biomolecules. 2020;10:1002.  doi: 10.3390/biom10071002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/biom10071002</ArticleId>
            <ArticleId IdType="pmc">PMC7408575</ArticleId>
            <ArticleId IdType="pubmed">32635659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kremer J.M., Emery P., Camp H.S., Friedman A., Wang L., Othman A.A., Khan N., Pangan A.L., Jungerwirth S., Keystone E.C. A Phase IIb Study of ABT-494, a selective JAK-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti–tumor necrosis factor therapy. Arthritis Rheumatol. 2016;68:2867–2877. doi: 10.1002/art.39801.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.39801</ArticleId>
            <ArticleId IdType="pmc">PMC5132116</ArticleId>
            <ArticleId IdType="pubmed">27389975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang F., Sun L., Wang S., Davis J.M., Matteson E.L., Murad M.H., Luo F., Vassallo R. Efficacy and safety of tofacitinib, baricitinib, and upadacitinib for rheumatoid arthritis: A systematic review and meta-analysis. Mayo Clin. Proc. 2020;95:1404–1419. doi: 10.1016/j.mayocp.2020.01.039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mayocp.2020.01.039</ArticleId>
            <ArticleId IdType="pubmed">32499126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jegatheeswaran J., Turk M., Pope J.E. Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: A systemic literature review. Immunotherapy. 2019;11:737–754. doi: 10.2217/imt-2018-0178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/imt-2018-0178</ArticleId>
            <ArticleId IdType="pubmed">30955397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reddy V., Cohen S. Role of Janus Kinase inhibitors in rheumatoid arthritis treatment. Curr. Opin. Rheumatol. 2021;33:300–306. doi: 10.1097/BOR.0000000000000792.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/BOR.0000000000000792</ArticleId>
            <ArticleId IdType="pubmed">33767091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harigai M. Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis. Rheumatology. 2019;58:34–42. doi: 10.1093/rheumatology/key287.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/key287</ArticleId>
            <ArticleId IdType="pmc">PMC6390880</ArticleId>
            <ArticleId IdType="pubmed">30806708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wollenhaupt J., Lee E.B., Curtis J.R., Silverfield J., Terry K., Soma K., Mojcik C., DeMasi R., Strengholt S., Kwok K., et al.  Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: Final results of a global, open-label, long-term extension study. Arthritis Res. Ther. 2019;21:1–18. doi: 10.1186/s13075-019-1866-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13075-019-1866-2</ArticleId>
            <ArticleId IdType="pmc">PMC6451219</ArticleId>
            <ArticleId IdType="pubmed">30953540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang J., Fu X., Chen X., Li Z., Huang Y., Liang C. Promising therapeutic targets for treatment of rheumatoid arthritis. Front. Immunol. 2021;12:2716. doi: 10.3389/FIMMU.2021.686155.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/FIMMU.2021.686155</ArticleId>
            <ArticleId IdType="pmc">PMC8299711</ArticleId>
            <ArticleId IdType="pubmed">34305919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang F., Luo Z. Adverse drug events associated with 5mg versus 10mg Tofacitinib (Janus kinase inhibitor) twice daily for the treatment of autoimmune diseases: A systematic review and meta-analysis of randomized controlled trials. Clin. Rheumatol. 2018;38:523–534. doi: 10.1007/s10067-018-4299-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10067-018-4299-4</ArticleId>
            <ArticleId IdType="pubmed">30242639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang F., Luo Z. Risk of adverse drug events observed with baricitinib 2 mg versus baricitinib 4 mg once daily for the treatment of rheumatoid arthritis: A systematic review and meta-analysis of randomized controlled trials. BioDrugs. 2018;32:415–423. doi: 10.1007/s40259-018-0304-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40259-018-0304-3</ArticleId>
            <ArticleId IdType="pubmed">30203252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takeuchi T., Tanaka Y., Tanaka S., Kawakami A., Iwasaki M., Katayama K., Rokuda M., Izutsu H., Ushijima S., Kaneko Y., et al.  Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. Ann. Rheum. Dis. 2019;78:1305–1319. doi: 10.1136/annrheumdis-2019-215164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2019-215164</ArticleId>
            <ArticleId IdType="pmc">PMC6788880</ArticleId>
            <ArticleId IdType="pubmed">31350269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Genovese M.C., Kalunian K., Gottenberg J.-E., Mozaffarian N., Bartok B., Matzkies F., Gao J., Guo Y., Tasset C., Sundy J.S., et al.  Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: The FINCH 2 randomized clinical trial. JAMA. 2019;322:315–325. doi: 10.1001/jama.2019.9055.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2019.9055</ArticleId>
            <ArticleId IdType="pmc">PMC6652745</ArticleId>
            <ArticleId IdType="pubmed">31334793</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gadina M., Schwartz D.M., O’Shea J.J. Decernotinib: A next-generation Jakinib. Arthritis Rheumatol. 2016;68:31–34. doi: 10.1002/art.39463.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.39463</ArticleId>
            <ArticleId IdType="pmc">PMC5026186</ArticleId>
            <ArticleId IdType="pubmed">26479275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen S., Curtis J.R., DeMasi R., Chen Y., Fan H., Soonasra A., Fleischmann R. Worldwide, 3-year, post-marketing surveillance experience with tofacitinib in rheumatoid arthritis. Rheumatol. Ther. 2018;5:283–291. doi: 10.1007/s40744-018-0097-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40744-018-0097-3</ArticleId>
            <ArticleId IdType="pmc">PMC5935628</ArticleId>
            <ArticleId IdType="pubmed">29470834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie W., Yang X., Huang H., Gao D., Ji L.L., Zhang Z. Risk of malignancy with non-TNFi biologic or tofacitinib therapy in rheumatoid arthritis: A meta-analysis of observational studies. Semin. Arthritis Rheum. 2020;50:930–937. doi: 10.1016/j.semarthrit.2020.08.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semarthrit.2020.08.007</ArticleId>
            <ArticleId IdType="pubmed">32906027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>U.S. National Library of Medicine  Safety Study of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor in Subjects with Rheumatoid Arthritis.  [(accessed on 15 October 2021)]; Available online:  https://clinicaltrials.gov/ct2/show/study/NCT02092467.</Citation>
        </Reference>
        <Reference>
          <Citation>Mease P., Charles-Schoeman C., Cohen S., Fallon L., Woolcott J., Yun H., Kremer J., Greenberg J., Malley W., Onofrei A., et al.  Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Ann. Rheum. Dis. 2020;79:1400–1413. doi: 10.1136/annrheumdis-2019-216761.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2019-216761</ArticleId>
            <ArticleId IdType="pmc">PMC7569391</ArticleId>
            <ArticleId IdType="pubmed">32759265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pfizer XELJANZ  5 mg Film-Coated Tablets—Summary of Product Characteristics.  [(accessed on 15 October 2021)].  Available online:  https://www.medicines.org.uk/emc/product/2500/smpc/print.</Citation>
        </Reference>
        <Reference>
          <Citation>Fujii T., Atsumi T., Okamoto N., Takahashi N., Tamura N., Nakajima A., Nakajima A., Matsuno H., Tsujimoto N., Nishikawa A., et al.  AB0249 safety of baricitinib in Japanese patients with rheumatoid arthritis (RA): The 2020 interim report from all-case post marketing surveillance in clinical practice. Ann. Rheum. Dis. 2021;80:1150. doi: 10.1136/annrheumdis-2021-eular.433.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2021-eular.433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>U.S. National Library of Medicine  A Study of Baricitinib in Participants with Rheumatoid Arthritis (RA-BRANCH)  [(accessed on 15 October 2021)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT04086745.</Citation>
        </Reference>
        <Reference>
          <Citation>U.S. National Library of Medicine  A Study of Baricitinib (LY3009104) in Participants with Rheumatoid Arthritis (RA-BRIDGE)  [(accessed on 15 October 2021)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT03915964.</Citation>
        </Reference>
        <Reference>
          <Citation>U.S. National Library of Medicine  A Study of Oral Upadacitinib Tablets to Assess the Change in Disease Symptoms in Adult Canadian Participants With Moderate to Severe Rheumatoid Arthritis (CLOSEUP)  [(accessed on 15 October 2021)]; Available online:  https://clinicaltrials.gov/ct2/show/study/NCT04574492.</Citation>
        </Reference>
        <Reference>
          <Citation>U.S. National Library of Medicine  A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Adult Participants with Moderate to Severe Active Rheumatoid Arthritis.  [(accessed on 15 October 2021)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT04541810.</Citation>
        </Reference>
        <Reference>
          <Citation>Perrot L., Hemon M., Busnel J.-M., Muis-Pistor O., Picard C., Zandotti C., Pham T., Roudier J., Desplat-Jego S., Balandraud N. First flare of ACPA-positive rheumatoid arthritis after SARS-CoV-2 infection. Lancet Rheumatol. 2021;3:6–8. doi: 10.1016/S2665-9913(20)30396-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2665-9913(20)30396-9</ArticleId>
            <ArticleId IdType="pmc">PMC7832430</ArticleId>
            <ArticleId IdType="pubmed">33521668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elemam N.M., Maghazachi A.A., Hannawi S. COVID-19 infection and rheumatoid arthritis: Mutual outburst cytokines and remedies. Curr. Med. Res. Opin. 2021;37:1–10. doi: 10.1080/03007995.2021.1906637.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/03007995.2021.1906637</ArticleId>
            <ArticleId IdType="pmc">PMC8040489</ArticleId>
            <ArticleId IdType="pubmed">33754931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Favalli E.G., Maioli G., Biggioggero M., Caporali R. Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic. Expert Rev. Clin. Immunol. 2021;17:561–571. doi: 10.1080/1744666X.2021.1908887.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/1744666X.2021.1908887</ArticleId>
            <ArticleId IdType="pubmed">33787418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smolen J.S., Aletaha D., Barton A., Burmester G.R., Emery P., Firestein G.S., Kavanaugh A., McInnes I.B., Solomon D.H., Strand V., et al.  Rheumatoid arthritis. Nat. Rev. Dis. Prim. 2018;4:1–23. doi: 10.1038/nrdp.2018.1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrdp.2018.1</ArticleId>
            <ArticleId IdType="pubmed">29417936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin Y.J., Anzaghe M., Schülke S. Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells. 2020;9:880.  doi: 10.3390/cells9040880.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cells9040880</ArticleId>
            <ArticleId IdType="pmc">PMC7226834</ArticleId>
            <ArticleId IdType="pubmed">32260219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Köhler B.M., Günther J., Kaudewitz D., Lorenz H.M. Current therapeutic options in the treatment of rheumatoid arthritis. J. Clin. Med. 2019;8:938.  doi: 10.3390/jcm8070938.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/jcm8070938</ArticleId>
            <ArticleId IdType="pmc">PMC6678427</ArticleId>
            <ArticleId IdType="pubmed">31261785</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
